---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-23-000009"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:51:12.615667+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Summit reports preliminary cash of at least $648M; shareholders authorize share increase and reverse split

## Summary
- Preliminary unaudited cash, equivalents and escrow balance no less than $648M as of Dec 31, 2022.
- Includes $300M upfront to Akeso held in escrow pending HSR clearance for ivonescimab license.
- Stockholders approved increasing authorized shares from 350M to 1B and a reverse stock split (1:5 to 1:10), board discretion within one year.
- Company to present at 41st J.P. Morgan Healthcare Conference on Jan 9, 2023, highlighting ivonescimab.

## SEC filing metadata
- accession: 0001599298-23-000009
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000009/0001599298-23-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000009/smmt-20230106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-23-000009
- JSON: https://secwatch.observer/filing/0001599298-23-000009.json
- Plain text: https://secwatch.observer/filing/0001599298-23-000009.txt

## Key facts
- Shareholder Votes
  Summit Therapeutics Inc. shareholders approved Amendment to Restated Certificate to increase authorized shares of common stock from 350,000,000 to 1,000,000,000 at the 2023-01-06 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-01-06
  source text: Proposal 1 For Against Abstain Broker Amendment No. 2 to Restated Certificate of Incorporation to increase the number of authorizes shares of common stock 188,470,028 1,585,907 165,798 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000009/0001599298-23-000009-index.htm
- Shareholder Votes
  Summit Therapeutics Inc. shareholders approved Amendment to Restated Certificate to effect a reverse stock split at a ratio in the range of 1-for-5 to 1-for-10 at the 2023-01-06 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-01-06
  source text: Proposal 2 For Against Abstain Broker Amendment No. 2 to Restated Certificate of Incorporation to effect a reverse stock split of the outstanding common stock 186,585,821 3,607,721 28,191 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000009/0001599298-23-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.